

# Claudio Vernieri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7936495/publications.pdf>

Version: 2024-02-01

67  
papers

2,365  
citations

257357

24  
h-index

233338

45  
g-index

67  
all docs

67  
docs citations

67  
times ranked

4260  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fasting-mimicking diet and hormone therapy induce breast cancer regression. <i>Nature</i> , 2020, 583, 620-624.	13.7	198
2	Evidence that Aurora B is implicated in spindle checkpoint signalling independently of error correction. <i>EMBO Journal</i> , 2011, 30, 1508-1519.	3.5	167
3	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	2.0	151
4	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	3.2	148
5	Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. <i>Cancer Discovery</i> , 2016, 6, 1315-1333.	7.7	137
6	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 53-66.	2.0	137
7	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. <i>Cancer Discovery</i> , 2022, 12, 90-107.	7.7	124
8	Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. <i>Nature Communications</i> , 2020, 11, 2332.	5.8	90
9	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1692-1704.	0.5	74
10	Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape. <i>Cell Metabolism</i> , 2021, 33, 2247-2259.e6.	7.2	63
11	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , 2020, 26, 992-994.	15.2	56
12	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54
13	Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. , 2020, 209, 107496.		52
14	The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)â€™Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. <i>Cancers</i> , 2021, 13, 1964.	1.7	50
15	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. <i>Annals of Surgery</i> , 2020, 271, 527-533.	2.1	44
16	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. <i>Nature Cancer</i> , 2022, 3, 251-261.	5.7	44
17	The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 8703.	1.6	43
18	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 57-73.	2.0	41

#	ARTICLE	IF	CITATIONS
19	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 347-352.	2.9	31
20	<b>Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer</b>. <i>Journal of Cellular Physiology</i> , 2019, 234, 1768-1779.	2.0	31
21	Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. <i>Cancers</i> , 2021, 13, 4013.	1.7	31
22	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	0.9	30
23	Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. <i>Cells</i> , 2020, 9, 2644.	1.8	30
24	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. <i>Future Oncology</i> , 2016, 12, 1251-1260.	1.1	29
25	Exploiting Fasting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019, 20, e413-e417.	1.1	27
26	HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. <i>Cancers</i> , 2021, 13, 4778.	1.7	27
27	Cancer Stem Cells: Devil or Savior- Looking behind the Scenes of Immunotherapy Failure. <i>Cells</i> , 2020, 9, 555.	1.8	26
28	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <i>Breast Cancer Research</i> , 2020, 22, 33.	2.2	26
29	Fasting-mimicking diet plus chemotherapy in breast cancer treatment. <i>Nature Communications</i> , 2020, 11, 4274.	5.8	24
30	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393.	1.9	23
31	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. <i>Cancer Letters</i> , 2021, 511, 77-87.	3.2	22
32	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. <i>Scientific Reports</i> , 2019, 9, 12993.	1.6	21
33	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 183-188.	1.4	20
34	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019, 144, 1704-1712.	2.3	20
35	The PAR complex controls the spatiotemporal dynamics of F-actin and the MTOC in directionally migrating leukocytes. <i>Journal of Cell Science</i> , 2014, 127, 4381-95.	1.2	19
36	Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. <i>European Journal of Cancer</i> , 2022, 172, 300-310.	1.3	19

#	ARTICLE	IF	CITATIONS
37	Adaptation to the spindle checkpoint is regulated by the interplay between Cdc28/Clbs and PP2ACdc55. <i>Journal of Cell Biology</i> , 2013, 202, 765-778.	2.3	18
38	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	1.6	18
39	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. <i>Cancers</i> , 2019, 11, 223.	1.7	18
40	Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process. <i>Current Biology</i> , 2018, 28, 28-37.e7.	1.8	17
41	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. <i>Clinical Breast Cancer</i> , 2019, 19, e306-e318.	1.1	16
42	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. <i>Oncotarget</i> , 2016, 7, 44841-44847.	0.8	15
43	Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 365-373.	1.1	12
44	DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. <i>Cells</i> , 2020, 9, 1260.	1.8	12
45	Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 815-828.	2.1	11
46	Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. <i>Cancers</i> , 2022, 14, 69.	1.7	9
47	Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 902.	1.3	8
48	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092727.	1.4	8
49	Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. <i>Pharmaceuticals</i> , 2020, 13, 385.	1.7	6
50	Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis. <i>Developmental Cell</i> , 2021, 56, 2607-2622.e6.	3.1	6
51	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. <i>Future Oncology</i> , 2017, 13, 1677-1683.	1.1	5
52	The AURORA of a New Way to Value Myeloid Immunosuppression in Cancer. <i>Cancer Research</i> , 2019, 79, 3169-3171.	0.4	5
53	Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 3314.	1.7	5
54	Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters. <i>Oncology</i> , 2021, 99, 84-95.	0.9	5

#	ARTICLE	IF	CITATIONS
55	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 7154.	1.8	5
56	Urachal carcinoma: towards a precision medicine. Translational Cancer Research, 2016, 5, S1307-S1310.	0.4	5
57	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities A Case Report with a 6-Year Follow-Up. Case Reports in Oncology, 2016, 9, 432-439.	0.3	4
58	Update on medical treatment of small intestinal neuroendocrine tumors. Expert Review of Anticancer Therapy, 2016, 16, 969-976.	1.1	4
59	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. Cancers, 2020, 12, 1153.	1.7	4
60	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. Cancers, 2020, 12, 617.	1.7	4
61	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). Clinical Cancer Research, 2021, 27, 3443-3455.	3.2	4
62	Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210791.	1.4	3
63	Cellular response upon proliferation in the presence of an active mitotic checkpoint. Life Science Alliance, 2019, 2, e201900380.	1.3	2
64	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open, 2020, 5, e000748.	2.0	2
65	Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097008.	1.4	2
66	Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211006960.	1.4	2
67	Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer. Annals of Translational Medicine, 2020, 8, 737-737.	0.7	1